ZSZeeshan H. Syedain

Zeeshan H. Syedain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zeeshan H. Syedain has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    18 Month patency of acellular bioengineered regenerative conduit as coronary artery bypass

    by Abrielle Krouse, Matthew Soule, Christina Gross, Mariah McMahon, Jacob Benkofske, Zeeshan H. Syedain

    Coronary artery bypass grafting remains the standard of care for complex coronary artery disease; however, outcomes are limited by failure or lack of suitable native vessels. Tissue-engineered vascular grafts have shown promise in peripheral applications, yet durable performance in coronary circulation remains unmet. In this study, tissue-engineered vessels are implanted with and without external support as coronary artery bypass grafts in an ovine model and anticoagulants are administered for 180 days. Unsupported vessels fail early due to kink-related thrombus, whereas external supported vessels achieve 100% patency at 180 days. Further, two animals are followed through 550 days without anticoagulant to maintain patency. The tissue engineered vessel explants demonstrate host-mediated remodeling including endothelium, no thrombus, minimal inflammatory response, and burst pressures exceeding native coronary bypass grafts. This study demonstrates preliminary, long-term patency after withdrawal of anticoagulation, with evidence of regenerative transformation into a living, functional vessel.

  • Open Access

    First European Clinical Implant of an Off-the-Shelf Bioengineered Blood Vessel for Coronary Artery Bypass

    by Mateusz Kuć, Matthew Soule, Zeeshan Syedain, Abrielle Krouse, Łukasz Wójcik, Monika Chomej-Dąbrowska, Patryk Król, Jerzy Pacholewicz

    Background: Coronary artery bypass grafting is the optimal revascularization strategy for patients with complex multivessel coronary artery disease. However, saphenous vein grafts are associated with high failure rates and donor site morbidity. Off-the-shelf tissue-engineered vascular grafts offer a potential solution for patients lacking suitable autologous vessels. Here, we report the first successful clinical implant of an acellular Tissue-Engineered Vessel (TEV) for coronary artery bypass grafting in Europe. Methods: A 73-year-old male with two-vessel disease and no suitable autologous vein underwent on-pump coronary artery bypass grafting using the left internal mammary artery to the left anterior descending artery and a 4 mm TEV to the right coronary artery. Results: Implant procedure followed standard surgical techniques, sutures and duration. The conduit handling was comparable to native vessels. Intraoperative flow measurements demonstrated excellent graft performance (TEV: 110 mL/min, Pulsatility Index 1.0). Postoperative recovery was uneventful. One-month computed tomography coronary angiography confirmed graft patency. Discussion: This case demonstrates the feasibility of using a bioengineered conduit for coronary revascularization in patients without suitable autologous grafts. If these findings are confirmed in larger trials, bioengineered vessels could expand surgical revascularization to patients without suitable autologous conduits and fundamentally alter conduit selection strategy in CABG. Conclusions: This first-in-Europe clinical implant demonstrates that an off-the-shelf acellular tissue-engineered vessel can meet the procedural, hemodynamics, and patency requirements of coronary artery bypass. These proof-of-concept results support progression to prospective multi-center evaluation.

  • Open Access

    Clinical Evaluation of Completely Biological Engineered Vessel for Coronary Artery Bypass

    by Adrian Ebner, Matthew Soule, Abrielle Krouse, Mariah McMahon, Zeeshan Syedain


  • Open Access

    18-Month Implant of a Transcatheter Pulmonary Valve Using Bioengineered Tissue Leaflets in Juvenile Sheep

    by Mariah McMahon, Abrielle Prunty, Jacob Benkofske, James Berry, Rika Kawakami, Rick Murphy, Renu Virmani, Gurumurthy Hiremath, Zeeshan Syedain

    Congenital valve disease, predominantly in the pulmonary position, requires multiple replacements as current bioprosthetic valves degrade and calcify over time. An allogenic, decellularized bioengineered tissue with minimum immune response and calcification would provide an ideal solution for young patients and could substantially improve the standard of care. In this study, a transcatheter pulmonary valve with bioengineered tissue leaflets on a self-expanding nitinol stent was implanted for up to 18 months in five juvenile sheep using an 18Fr transapical delivery system. Serial echo monitoring showed an increase in cardiac output as the juvenile sheep grew without any decrease in effective orifice area (>2 cm 2 ) or increase in pressure gradients (<10 mmHg for both peak and mean). No valvular regurgitation, leaflet thickening, or tissue abnormality was reported at any time points. Micro-CT and histological assessment showed mild calcification and mild thrombosis. The 18-month implants in the highly calcific juvenile sheep model showed no loss of function and no deterioration of the bioengineered tissue, suggesting a suitable alternative leaflet material for younger patients where functional longevity is critical.


  • Open Access

    Evaluation of an engineered vascular graft exhibiting somatic growth in lambs to model repair of absent pulmonary artery branch

    by Zeeshan H. Syedain, Matthew Lahti, Gurumurthy Hiremath, James Berry, John P. Carney, Jill Schappa Faustich, Tate Shannon, Andrea Rivera, Hadi Wiputra, Zhitian Shi, et al.

    Background Growth is the holy grail of tissue implants in pediatrics. No vascular graft currently in use for surgical repairs of congenital heart defects has somatic growth capacity. Methods Biologically-engineered grafts (6 mm) grown from donor ovine fibroblasts in a sacrificial fibrin gel were implanted into the left pulmonary branch of 3-month old lambs for 3, 6, and 18 months. A control group of Propaten® PTFE grafts was implanted for 6 months. Results The engineered grafts exhibit extensive site-appropriate recellularization after only 3 months and near-normal increase of diameter from the preimplant value of 6 mm to 12.9 mm and also a doubling of length from 6.0 mm to 13.0 mm at 6 months (n = 3) associated with apparent somatic graft growth (collagen content increase of 265% over 18-month, n = 2), along with excellent hemodynamics and no calcification, in contrast to the Propaten® grafts. The left-right flow distribution is nearly 50–50 for the engineered grafts at 6 months (n = 3) compared to about 20–80 for the Propaten® grafts (n = 3), which have less than one-half the diameter, a 6-fold higher pressure gradient, and stunted vascular development downstream of the graft. The engineered grafts exhibit a stable diameter over months 12–18 when the lambs become adult sheep (n = 2). Conclusions This study supports the use of these regenerative grafts with somatic growth capacity for clinical trial in patients born with a unilateral absent pulmonary artery branch, and it shows their potential for improving development of the downstream pulmonary vasculature.


  • First-in-human evaluation of a biological regenerative vascular conduit for hemodialysis access

    by Adrian Ebner, Santiago Gallo, Juan Castellano, Maria Filartiga, Allie Haarstad, Cory Pries, Kate Gahlbeck, Mariah McMahon, Camila Herrera, Martha Avila, et al.

    Introduction: The long-term survival and low complication rate of autogenous fistulas for hemodialysis access is often offset by early thrombosis and slow or failed maturation leading to the use of central venous catheters. A regenerative material may have the potential to overcome these limitations. A completely biological acellular vascular conduit was investigated in this first-in-human clinical study. Methods: With approval of the ethics board and patients’ informed consent, five subjects were enrolled based on predetermined inclusion criteria. Five patients underwent implant of a novel acellular, biological tissue conduit (TRUE AVC™) in the upper arm in a curved configuration between brachial artery and axillary vein. After maturation, standard dialysis was commenced through the new access. Patients were followed up to 26 weeks with ultrasound and physical exam. Serum samples were evaluated for an immune response to the novel allogeneic human tissue implant. Results: This new tissue conduit handled well surgically, with properties similar to that of native human vein. Post procedure conduit flow was excellent in all cases, averaging 1098 ± 388 ml/min at week 4 and remaining stable through 1248 ± 355 ml/min at 26 weeks. Surgical site healing was normal with no edema or erythema by week 4. Six-month primary assisted patency was 80% and secondary patency was 100%. Prescribed dialysis was successfully delivered without infection, and there was no significant change in conduit diameter. Serum testing showed no increase in PRA or IgG specific to the TRUE AVC. One implant required intervention at 5 months with thrombectomy and covered stent procedure. Conclusion: This first-in-human 6-month study with favorable patency and low complication rate establishes the initial safety and feasibility of this novel biological tissue conduit for dialysis access in patients with end-stage kidney disease. Its mechanical durability and lack of immune response establishes TRUE AVC as a potential regenerative material for clinical use.


  • Pediatric tri-tube valved conduits made from fibroblast-produced extracellular matrix evaluated over 52 weeks in growing lambs

    by Zeeshan H. Syedain, Bee Haynie, Sandra L. Johnson, Matthew Lahti, James Berry, John P. Carney, Jirong Li, Ryan C. Hill, Kirk C. Hansen, Greeshma Thrivikraman, et al.

    A pulmonary replacement valve made from three tubes of cell-derived matrix functioned for 52 weeks in lambs and calcified less than commercial valves.


  • A completely biological “off-the-shelf” arteriovenous graft that recellularizes in baboons

    by Zeeshan H. Syedain, Melanie L. Graham, Ty B. Dunn, Timothy O’brien, Sandra L. Johnson, Robert J. Schumacher, Robert T. Tranquillo

    A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.